Strategies for Optimizing Supplier Relationship Management at DCAT Sharp Sourcing

How pharmaceutical companies and CDMOs, CMOs, and suppliers collaborate is a key factor in being able to meet goals for cost reduction, cost avoidance, and value creation. How does your company stand?

A myriad of issues can impede as well as facilitate supplier relations. Understanding the pitfalls as well as the solutions is key for meeting desired business goals. DCAT Sharp Sourcing, being held, Tuesday, July 12, in New Brunswick, New Jersey, provides key insight from leading pharmaceutical industry executives on what works and what doesn’t.

Developed by DCAT’s Supply Management Committee and the Education Committee’s Sharp Sourcing Supplier Program Task Force, Sharp Sourcing will feature specialized education forums for buyers and suppliers and joint sessions on supply chain optimization/CMO integration, right-first time metrics, and procurement analytics and supply risk management. The event will also feature a keynote address on how to foster innovation with your suppliers for a competitive advantage by award-winning entrepreneur and star of ABC’s Shark Tank Daymond John.

Of particular value are the Buyers’ and Suppliers’ Forums, specialized educational sessions that provide case studies and practical insight from leading pharmaceutical and biopharmaceutical companies. The Buyers’ Forum is designed specifically for professionals involved in sourcing, procurement, supply management, and external manufacturing. It will feature three topics with roundtable discussions: Procurement’s influence in specification management; sustainable procurement; and supplier metrics: going beyond scorecards with executives from Mallinckrodt Pharmaceuticals, Biogen, and Eli Lilly and Company providing insight.

In the Suppliers’ Forum, executives from Bristol-Myers Squibb, Novartis, Pfizer, PwC, and others will provide customer-centric perspectives for CDMOs, CMOs and suppliers on different aspects of supplier relationship management. Key topics to be addressed include: (1) managing supplier consolidation: (2) managing an integrated supply chain and network integration; (3) strategic partnerships/collaboration, including supplier innovation; (4) inter-supply cooperation/management with raw material suppliers, CDMOs, CMOs; and (5) managing working capital requirements (i.e., payment terms, inventory holding, and other supply related issues).

In the joint afternoon session, buyer and suppliers come together for presentations of common interest. J&J’s Janssen will kick off the joint afternoon session with a presentation on supply chain optimization and CMO integration that will provide insights on how to build collaborative external partnerships and optimize active pharmaceutical ingredient supply networks. A panel of leading industry experts, including executives from Pfizer and Teva, then discuss how pharmaceutical companies and suppliers can partner and achieve operational excellence and meet desired metrics, such as right-first time, in the manufacture of drug substances and drug products. In the final presentation, Merck & Co. will discuss how to use value-based metrics to more effectively assess and mitigate supply risk.

Information on Sharp Sourcing, including how to register, may be found here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

Emerging Pharma: The Impact and Latest on Tariffs & Changing Healthcare Policy

By
Emerging Pharma companies are an important partner to larger companies in drug development and as customers to CDMOs/CMOs. What has been the impact thus far on evolving US trade policy, including tariffs, and changes in healthcare policy and funding? DCAT Value Chain Insights takes an inside look.

President Trump Issues Executive Order for Most-Favored Nation Drug Pricing

By
President Donald Trump issued an Executive Order this week to lay out a plan to implement most-favored-nation drug pricing as a way to reduce differentials in drug pricing between the US and foreign countries as means to lower the cost of Rx drugs in the US. What’s the impact of pharma manufactuers?

President Trump Signs Executive Order To Increase US-Based Pharma Manufacturing

By
President Donald Trump signed an Executive Order this week to facilitate drug manufacturing in the US, including calling for measures to streamline FDA and EPA review of domestic pharma manufacturing and enhance review of foreign drug-manufacturing facilities. What’s next?

CDMO/CMO Expansion Update: Riding the Strength of TIDES

By
Riding the strength of GLP-1 agonists and renewed interest in peptide-based development, several CDMOs are proceeding with large-scale investments in peptide development and manufacturing as other companies are joining the peptide space.